This study aims to test if curcumin, a substance from turmeric, can help treat anal high-grade squamous intraepithelial lesions (aHSIL), which are pre-cancerous cells, in people with HIV. These lesions can lead to cancer if untreated. The study avoids current treatments like ablation or surgery, which can have side effects. Instead, participants will receive curcumin directly on the affected area for 14 days. This is a Phase I trial, meaning researchers will test different doses to find the safest amount. They want to see if the curcumin is safe and if it can help heal these abnormal cells.

Key Points:

• Participants must be 35 or older with certain types of anal lesions and HIV.
• The study lasts 14 days, with doses adjusted for safety.
• Participants will answer questions to help improve future studies.

People with certain medical conditions, history of anal cancer, or some substance use issues may not qualify. Pregnant women or those planning pregnancy soon are also excluded. This trial is important for finding safer ways to treat pre-cancerous anal lesions without surgery. Eligible individuals can help advance this research.